Walleye Capital LLC Has $6.83 Million Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX)

Walleye Capital LLC lifted its stake in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 70.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 488,453 shares of the company's stock after purchasing an additional 201,282 shares during the quarter. Walleye Capital LLC owned about 0.63% of Travere Therapeutics worth $6,833,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also made changes to their positions in TVTX. Vanguard Group Inc. boosted its position in shares of Travere Therapeutics by 13.6% during the first quarter. Vanguard Group Inc. now owns 6,265,829 shares of the company's stock worth $48,310,000 after buying an additional 750,686 shares during the period. Price T Rowe Associates Inc. MD raised its stake in shares of Travere Therapeutics by 10.5% during the first quarter. Price T Rowe Associates Inc. MD now owns 31,009 shares of the company's stock valued at $240,000 after purchasing an additional 2,948 shares in the last quarter. Talbot Financial LLC acquired a new stake in Travere Therapeutics in the second quarter worth about $522,000. SG Americas Securities LLC acquired a new stake in Travere Therapeutics in the second quarter worth about $139,000. Finally, Assenagon Asset Management S.A. grew its position in Travere Therapeutics by 912.5% in the 2nd quarter. Assenagon Asset Management S.A. now owns 2,214,099 shares of the company's stock valued at $18,200,000 after buying an additional 1,995,419 shares in the last quarter.

Travere Therapeutics Trading Up 0.6 %

NASDAQ TVTX traded up $0.11 on Friday, hitting $18.81. 1,494,031 shares of the stock were exchanged, compared to its average volume of 1,321,473. Travere Therapeutics, Inc. has a 52-week low of $5.12 and a 52-week high of $20.33. The company has a market capitalization of $1.47 billion, a price-to-earnings ratio of -4.13 and a beta of 0.70. The company has a debt-to-equity ratio of 24.96, a current ratio of 1.71 and a quick ratio of 1.68. The company's 50-day moving average price is $17.18 and its two-hundred day moving average price is $11.83.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last posted its earnings results on Thursday, October 31st. The company reported ($0.70) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.71) by $0.01. The business had revenue of $62.90 million for the quarter, compared to analyst estimates of $60.87 million. Travere Therapeutics had a negative net margin of 172.75% and a negative return on equity of 537.74%. Travere Therapeutics's revenue was up 69.6% compared to the same quarter last year. During the same period last year, the business posted ($1.17) EPS. Research analysts predict that Travere Therapeutics, Inc. will post -3.94 EPS for the current year.

Insider Buying and Selling

In other Travere Therapeutics news, SVP William E. Rote sold 4,387 shares of Travere Therapeutics stock in a transaction on Monday, September 9th. The shares were sold at an average price of $11.52, for a total transaction of $50,538.24. Following the sale, the senior vice president now owns 84,455 shares in the company, valued at $972,921.60. The trade was a 4.94 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Jula Inrig sold 2,191 shares of the stock in a transaction on Monday, September 9th. The shares were sold at an average price of $11.52, for a total transaction of $25,240.32. Following the completion of the transaction, the insider now owns 62,633 shares of the company's stock, valued at approximately $721,532.16. This represents a 3.38 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 122,797 shares of company stock valued at $1,725,559. Insiders own 3.75% of the company's stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on TVTX shares. Scotiabank upped their price target on shares of Travere Therapeutics from $23.00 to $27.00 and gave the stock a "sector outperform" rating in a research note on Friday, November 1st. Guggenheim upped their target price on Travere Therapeutics from $23.00 to $41.00 and gave the stock a "buy" rating in a research report on Wednesday, October 9th. HC Wainwright lowered their price target on Travere Therapeutics from $23.00 to $18.00 and set a "buy" rating on the stock in a research report on Friday, September 27th. Canaccord Genuity Group dropped their price objective on Travere Therapeutics from $23.00 to $22.00 and set a "buy" rating on the stock in a research note on Monday, September 30th. Finally, JPMorgan Chase & Co. raised their target price on Travere Therapeutics from $20.00 to $23.00 and gave the company an "overweight" rating in a research note on Friday, September 13th. Two equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $22.62.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.